ストックスクリーナーアプリを入手
3.28
6.02%
-0.21
前日終値:
$3.49
開ける：
$3.51
24時間の取引高:
2.46M
Relative Volume:
0.51
時価総額：
$482.81M
収益：
$8.37M
当期純損益:
$-69.66M
株価収益率:
-5.853
EPS:
-0.5604
ネットキャッシュフロー:
$-51.45M
1週間 パフォーマンス:
-14.36%
1か月 パフォーマンス:
-38.35%
6か月 パフォーマンス:
-17.59%
1年 パフォーマンス:
+60.00%
1日の値動き範囲:
$3.245
$3.53
1週間の範囲:
$3.245
$3.835
52週間の値動き範囲:
$1.88
$6.5999
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Compare ACRS vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
3.28 | 482.81M | 8.37M | -69.66M | -51.45M | -0.5604 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-09-01 | 開始されました | Canaccord Genuity | Buy |
| 2026-05-05 | 開始されました | Guggenheim | Buy |
| 2026-04-16 | 開始されました | Oppenheimer | Outperform |
| 2025-07-10 | 再開されました | Piper Sandler | Overweight |
| 2025-05-28 | 開始されました | Wedbush | Outperform |
| 2025-03-18 | 再開されました | Cantor Fitzgerald | Overweight |
| 2024-12-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | アップグレード | BTIG Research | Neutral → Buy |
| 2024-11-19 | アップグレード | Jefferies | Hold → Buy |
| 2024-11-19 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | 開始されました | Evercore ISI | Outperform |
| 2022-12-14 | 開始されました | Stifel | Buy |
| 2022-12-01 | 開始されました | Goldman | Buy |
| 2022-10-06 | 開始されました | BTIG Research | Buy |
| 2021-07-23 | 再開されました | Jefferies | Buy |
| 2021-06-15 | 開始されました | Piper Sandler | Overweight |
| 2021-04-21 | 開始されました | H.C. Wainwright | Buy |
| 2019-10-22 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | 開始されました | SVB Leerink | Outperform |
| 2018-03-28 | 再開されました | Leerink Partners | Outperform |
| 2018-02-09 | 開始されました | Guggenheim | Buy |
| 2017-06-16 | 開始されました | Cantor Fitzgerald | Overweight |
| 2016-11-29 | 開始されました | Leerink Partners | Outperform |
| 2016-09-30 | 開始されました | JMP Securities | Mkt Outperform |
| 2016-06-10 | 開始されました | Guggenheim | Buy |
| 2015-11-02 | 開始されました | Citigroup | Buy |
| 2015-11-02 | 開始されました | Jefferies | Buy |
すべてを表示
Aclaris Therapeutics Inc (ACRS) 最新ニュース
Aclaris Therapeutics, Inc. (ACRS) options chain - Yahoo Finance UK
MCPMF Stock Price and Chart — OTC:MCPMF - TradingView
Cantor Fitzgerald reiterates Aclaris Therapeutics stock rating - Investing.com
Cantor Fitzgerald reiterates Aclaris stock rating on LP opportunity - Investing.com
Aclaris Therapeutics, Inc. (8AT.F) stock price, news, quote and history - Yahoo Finance UK
Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength? - Eastern Progress
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade - Eastern Progress
Cantor Fitzgerald reiterates Aclaris Therapeutics stock rating By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Aclaris Therapeutics stock rating - Investing.com
Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock? - Yahoo Finance
Aclaris at Cantor Fitzgerald conference: pipeline, cash, catalysts By Investing.com - Investing.com South Africa
Aclaris at Cantor Fitzgerald conference: pipeline, cash, catalysts By Investing.com - Investing.com Nigeria
Aclaris at Cantor Fitzgerald conference: pipeline, cash, catalysts - Investing.com
Aclaris at Cantor Fitzgerald conference: pipeline, cash, catalysts - Investing.com India
Aclaris at Cantor Fitzgerald conference: pipeline, cash, catalysts By Investing.com - Investing.com UK
Aclaris CEO to Detail Drug Pipeline at Cantor Conference - MyChesCo
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - Investing News Network
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - Yahoo Finance
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - GlobeNewswire
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - GlobeNewswire
Canaccord initiates Aclaris stock with buy rating on pipeline potential By Investing.com - Investing.com South Africa
Canaccord initiates Aclaris stock with buy rating on pipeline potential By Investing.com - Investing.com Australia
Canaccord initiates Aclaris stock with buy rating on pipeline potential By Investing.com - Investing.com Canada
Canaccord initiates Aclaris stock with buy rating on pipeline potential - Investing.com India
CCORF Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $10 - Moomoo
Canaccord Genuity Initiates Aclaris Therapeutics at Buy With $10 Price Target - Yahoo Finance
Piper Sandler reiterates Aclaris stock rating on asthma data By Investing.com - Investing.com India
Piper Sandler reiterates Aclaris stock rating on asthma data By Investing.com - Investing.com Canada
Piper Sandler reiterates Aclaris stock rating on asthma data By Investing.com - Investing.com Nigeria
Piper Sandler reiterates Aclaris stock rating on asthma data By Investing.com - Investing.com UK
ETFs Investing in Aclaris Therapeutics, Inc. Stocks - TradingView
Aclaris Therapeutics (NASDAQ:ACRS) Stock: What Comes Next? - Kalkine Media
Aclaris Therapeutics (NASDAQ:ACRS) Trading 4.7% HigherWhat's Next? - MarketBeat
Aclaris Therapeutics (ACRS) Edges Lower by 1.37% as Shares Test Key Technical FloorRevenue Growth Stocks - vinanet.vn
Sei Investments Co. Makes New Investment in Aclaris Therapeutics, Inc. $ACRS - MarketBeat
Dimensional Fund Advisors LP Has $1.91 Million Stock Position in Aclaris Therapeutics, Inc. $ACRS - MarketBeat
FDA Fast Track Status Advances Aclaris Lichen Planus Drug - MyChesCo
HC Wainwright Has Pessimistic Outlook of ACRS Q3 Earnings - MarketBeat
Renaissance Technologies LLC Has $1.89 Million Stake in Aclaris Therapeutics, Inc. $ACRS - MarketBeat
Aclaris Therapeutics, Inc. (ACRS) stock price, news, quote and history - Yahoo Finance Australia
Aclaris Raises Capital as Drug Pipeline Spending Accelerates - MyChesCo
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Buy" by Brokerages - MarketBeat
Aclaris Therapeutics, Inc. (ACRS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade - Zacks Investment Research
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade - Yahoo Finance
Weekly Recap: Q2 loss, runway into 2028 and Fast Track for modzatinib - TradingView
H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Aclaris Therapeutics (ACRS) Stock Drifts Lower As Losses Deepen On Thin Revenue - simplywall.st
Aclaris Updates At-The-Market Equity Sales Agreement - The Globe and Mail
Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Down 6%Here's What Happened - MarketBeat
Aclaris Therapeutics Inc (ACRS) 財務データ
収益
当期純利益
現金流量
EPS
4.22%
大文字化:
|
ボリューム (24 時間):